410 related articles for article (PubMed ID: 16688294)
1. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
[TBL] [Abstract][Full Text] [Related]
2. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
[TBL] [Abstract][Full Text] [Related]
3. [Vancomycin and teicoplanin use as antibiotic prophylaxis in cardiac surgery: pharmacoeconomic study].
Codina C; Miró JM; Tuset M; Claramonte J; Gomar C; Gotsens R; Gómez B; Suárez S; Abellana R; Ascaso C; Cartaña R; Rodríguez E; Asenjo M; Carné X; Trilla A; Marco F; Gómez J; Brunet M; Pomar JL; Gatell JM; Ribas J
Med Clin (Barc); 2000; 114 Suppl 3():54-61. PubMed ID: 10994565
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
Hung YP; Lee NY; Chang CM; Lee HC; Wu CJ; Chen PL; Lee CC; Chung CH; Ko WC
Clin Ther; 2009 Sep; 31(9):1977-86. PubMed ID: 19843487
[TBL] [Abstract][Full Text] [Related]
5. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
Wilcox M; Nathwani D; Dryden M
J Antimicrob Chemother; 2004 Feb; 53(2):335-44. PubMed ID: 14729745
[TBL] [Abstract][Full Text] [Related]
6. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections.
Laohavaleeson S; Barriere SL; Nicolau DP; Kuti JL
Pharmacotherapy; 2008 Dec; 28(12):1471-82. PubMed ID: 19025428
[TBL] [Abstract][Full Text] [Related]
8. Current treatment of gram-positive infections: focus on efficacy, safety, and cost minimalization analysis of teicoplanin.
Crane VS; Garabedian-Ruffalo SM
Hosp Formul; 1992 Dec; 27(12):1199-200, 1203-4, 1207-10. PubMed ID: 10122506
[TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Shen WC; Chiang YC; Chen HY; Chen TH; Yu FL; Tang CH; Sue YM
Nephrology (Carlton); 2011 Nov; 16(8):697-703. PubMed ID: 21707841
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University Hospital.
Sancar AA; Yegenoglu S; de Vries R; Postma MJ; Simsek N; Pechlivanoglou P; Unal S
Pharm World Sci; 2008 Dec; 30(6):916-23. PubMed ID: 18803030
[TBL] [Abstract][Full Text] [Related]
11. Cost of Gram-negative resistance.
Evans HL; Lefrak SN; Lyman J; Smith RL; Chong TW; McElearney ST; Schulman AR; Hughes MG; Raymond DP; Pruett TL; Sawyer RG
Crit Care Med; 2007 Jan; 35(1):89-95. PubMed ID: 17110877
[TBL] [Abstract][Full Text] [Related]
12. Teicoplanin vs vancomycin: cost-effectiveness comparisons.
Rybak MJ
Hosp Formul; 1993 Jan; 28 Suppl 1():28-32. PubMed ID: 10123835
[TBL] [Abstract][Full Text] [Related]
13. A pharmacoeconomic model to evaluate antibiotic costs.
Garrelts JC; Horst WD; Silkey B; Gagnon S
Pharmacotherapy; 1994; 14(4):438-45. PubMed ID: 7937280
[TBL] [Abstract][Full Text] [Related]
14. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation.
D'Antonio D; Staniscia T; Piccolomini R; Fioritoni G; Rotolo S; Parruti G; Di Bonaventura G; Manna A; Savini V; Fiorilli MP; Di Giovanni P; Francione A; Schioppa F; Romano F
Chemotherapy; 2004 Jun; 50(2):81-7. PubMed ID: 15211082
[TBL] [Abstract][Full Text] [Related]
15. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
Davis SL; McKinnon PS; Hall LM; Delgado G; Rose W; Wilson RF; Rybak MJ
Pharmacotherapy; 2007 Dec; 27(12):1611-8. PubMed ID: 18041881
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacoeconomic study of vancomycin and teicoplanin in intensive care patients.
Abad F; Calbo F; Zapater P; Rodríguez-Vilanova F; García-Pérez L; Sacristán JA
Int J Antimicrob Agents; 2000 Jun; 15(1):65-71. PubMed ID: 10856679
[TBL] [Abstract][Full Text] [Related]
17. Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.
Spencer CM; Bryson HM
Pharmacoeconomics; 1995 Apr; 7(4):357-74. PubMed ID: 10155323
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacoeconomic assessment of daptomycin as first-line therapy for bacteraemia and complicated skin and skin structure infections caused by gram-positive pathogens in Spain].
Grau S; Rebollo P; Cuervo J; Gil-Parrado S
Rev Esp Quimioter; 2011 Sep; 24(3):154-63. PubMed ID: 21947099
[TBL] [Abstract][Full Text] [Related]
19. Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial.
López H; Li JZ; Balan DA; Willke RJ; Rittenhouse BE; Mozaffari E; Vidal G; Zitto T; Tang T
Clin Ther; 2003 Jun; 25(6):1846-71. PubMed ID: 12860502
[TBL] [Abstract][Full Text] [Related]
20. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus.
Menzin J; Marton JP; Meyers JL; Carson RT; Rothermel CD; Friedman M
Am J Infect Control; 2010 Feb; 38(1):44-9. PubMed ID: 19762120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
